CUIDADO FARMACÊUTICO AO PACIENTE PORTADOR DE DOENÇA HEPÁTICA GORDUROSA NÃO ALCOÓLICA

O fácil acesso ao consumo alimentício não designa necessariamente uma dieta adequada da população, que ao se tornar inadequada em excesso pode causar distúrbios patológicos gastrointestinais como a obesidade, podendo ser sequenciada por alterações morfológicas e doenças crônicas, sendo uma delas a Esteatose Hepática ou Doença Hepática Gordurosa Não Alcoólica (DHGNA). O seguinte trabalho tem como objetivo aplicar o cuidado farmacêutico ao paciente portador de DHGNA. Remete-se a um estudo de caso do tipo descritivo, realizado com paciente do sexo feminino, residente da cidade de Quixadá-CE, com dados coletados através de variáveis e acompanhamento para complementação do estudo, posteriormente ocorreu a complementação do trabalho através de pesquisas bibliográficas realizadas nas bases BVS, Scielo e Google Acadêmico. Foram obedecidos os aspectos éticos exigidos na Resolução 466/12, mediante assinatura do Termo de Consentimento Livre e Esclarecido (TCLE).  Por fim, após a intervenção medicamentosa e nutricional, foi possível observar uma melhoria na manutenção da dignidade e prolongamento do tempo de vida da paciente, proporcionando o mínimo de sofrimento. O presente trabalho reforça o papel do farmacêutico visando a boa evolução do paciente, a otimização da terapia, a implementação dos cuidados e orientação correta quanto ao estado e a terapia requerida.

Cardiovascular Statistics - Brazil 2021.

This is the 2021 edition of the Cardiovascular Statistics – Brazil , a multi-institutional effort to periodically provide updated information on the epidemiology of heart diseases and stroke in Brazil. The report incorporates official statistics provided by the Brazilian Ministry of Health and other government agencies, by the GBD project led by the IHME of the University of Washington, as well as data generated by other sources and scientific studies, such as cohorts and registries, on CVDs and their risk factors. The document is directed to researchers, clinicians, patients, healthcare policy makers, media professionals, the public, and others who seek comprehensive national data available on heart disease and stroke

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio